Skip to main content
. 2019 Apr 2;20(7):1631. doi: 10.3390/ijms20071631

Table 1.

Baseline characteristics of patients involved in the study.

Variable All Patients (N = 32)
Sex
Female 12
Male 20
Age
<60 10
≥60 22
Histology
Squamous 10
Non-Squamous 21
Immunotherapy treatment
Pembrolizumab 9
Nivolumab 15
Atezolizumab 8
PDL1 status
0% 8
1–4% 3
5–49% 8
≥50% 7
Undetermined 6
Mutation status
No 30
EGFR 1
ROS1 1
Smoking status
Smoker 27
Non-smoker 5
Treatment line
1st 5
2nd 20
3rd 5
4th or higher 2
Previous systemic therapies (previous 3 months)
Platinum-based therapy 12
Non-platinum based therapy 8
No 12
ECOG
0–1 25
2–4 7
Undetermined 0
GRImScore
0–1 15
2–3 7
Undetermined 9
Liver metastases
No 23
Yes 9
Number of sites involved
≤2 9
≥3 23
CD4 THD Profiling
G1 profile 14
G2 profile 18
Responses
Partial response 10
Progression disease 19
Stable disease 3